Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 90

Similar articles for PubMed (Select 23861845)

1.

Recent HbA1c values and mortality risk in type 2 diabetes. population-based case-control study.

Nicholas J, Charlton J, Dregan A, Gulliford MC.

PLoS One. 2013 Jul 5;8(7):e68008. doi: 10.1371/journal.pone.0068008. Print 2013.

2.

HbA1c levels and all-cause mortality in type 2 diabetic patients: epidemiological evidence of the need for personalised therapeutic targets.

Monami M, Vitale V, Lamanna C, Bartoli N, Martelli D, Zannoni S, Antenore A, Toffanello G, Marchionni N, Mannucci E.

Nutr Metab Cardiovasc Dis. 2013 Apr;23(4):300-6. doi: 10.1016/j.numecd.2012.01.003. Epub 2012 May 26.

PMID:
22633797
3.

Associations of HbA1c and educational level with risk of cardiovascular events in 32,871 drug-treated patients with Type 2 diabetes: a cohort study in primary care.

Östgren CJ, Sundström J, Svennblad B, Lohm L, Nilsson PM, Johansson G.

Diabet Med. 2013 May;30(5):e170-7. doi: 10.1111/dme.12145. Epub 2013 Mar 13.

4.

Evaluation of four novel genetic variants affecting hemoglobin A1c levels in a population-based type 2 diabetes cohort (the HUNT2 study).

Hertel JK, Johansson S, Ræder H, Platou CG, Midthjell K, Hveem K, Molven A, Njølstad PR.

BMC Med Genet. 2011 Feb 4;12:20. doi: 10.1186/1471-2350-12-20.

5.

Patients newly diagnosed with clinical type 2 diabetes mellitus but presenting with HbA1c within normal range: 19-year mortality and clinical outcomes.

Veloso AG, Siersma V, Heldgaard PE, de Fine Olivarius N.

Prim Care Diabetes. 2013 Apr;7(1):33-8. doi: 10.1016/j.pcd.2012.09.001. Epub 2012 Oct 5.

PMID:
23041240
6.

Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.

Charbonnel B, Steinberg H, Eymard E, Xu L, Thakkar P, Prabhu V, Davies MJ, Engel SS.

Diabetologia. 2013 Jul;56(7):1503-11. doi: 10.1007/s00125-013-2905-1. Epub 2013 Apr 19.

PMID:
23604551
7.

New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR).

Eeg-Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Svensson AM, Gudbjörnsdóttir S, Eliasson B.

J Intern Med. 2010 Nov;268(5):471-82. doi: 10.1111/j.1365-2796.2010.02265.x.

PMID:
20804517
8.

Use of haemoglobin A1c to detect impaired fasting glucose or Type 2 diabetes in a United Kingdom community based population.

Kumaravel B, Bachmann MO, Murray N, Dhatariya K, Fenech M, John WG, Scarpello TJ, Sampson MJ; University of East Anglia Impaired Fasting Glucose (UEA-IFG) Study Group.

Diabetes Res Clin Pract. 2012 May;96(2):211-6. doi: 10.1016/j.diabres.2011.12.004. Epub 2012 Jan 17.

PMID:
22257419
9.

The impact of metabolic control and QTc prolongation on all-cause mortality in patients with type 2 diabetes and foot ulcers.

Fagher K, Löndahl M.

Diabetologia. 2013 May;56(5):1140-7. doi: 10.1007/s00125-013-2860-x. Epub 2013 Feb 12.

PMID:
23404446
10.

Association between HbA1c and cardiovascular disease mortality in older Hong Kong Chinese with diabetes.

Xu L, Chan WM, Hui YF, Lam TH.

Diabet Med. 2012 Mar;29(3):393-8. doi: 10.1111/j.1464-5491.2011.03456.x.

PMID:
21916977
11.

Hemoglobin A1c, comorbid conditions and all-cause mortality in older patients with diabetes: a retrospective 9-year cohort study.

Grembowski D, Ralston JD, Anderson ML.

Diabetes Res Clin Pract. 2014 Nov;106(2):373-82. doi: 10.1016/j.diabres.2014.07.017. Epub 2014 Jul 29.

PMID:
25151226
12.

Glycemic control and risk of cardiovascular disease hospitalization and all-cause mortality.

Nichols GA, Joshua-Gotlib S, Parasuraman S.

J Am Coll Cardiol. 2013 Jul 9;62(2):121-7. doi: 10.1016/j.jacc.2013.04.031. Epub 2013 May 9.

13.

Impact of diabetes control on mortality by race in a national cohort of veterans.

Hunt KJ, Gebregziabher M, Lynch CP, Echols C, Mauldin PD, Egede LE.

Ann Epidemiol. 2013 Feb;23(2):74-9. doi: 10.1016/j.annepidem.2012.11.002. Epub 2012 Dec 11.

PMID:
23238350
14.

Utility of hemoglobin A1c in predicting diabetes risk.

Edelman D, Olsen MK, Dudley TK, Harris AC, Oddone EZ.

J Gen Intern Med. 2004 Dec;19(12):1175-80.

15.

Short-term impact of HbA1c on morbidity and all-cause mortality in people with type 2 diabetes: a Danish population-based observational study.

Skriver MV, Støvring H, Kristensen JK, Charles M, Sandbæk A.

Diabetologia. 2012 Sep;55(9):2361-70. doi: 10.1007/s00125-012-2614-1. Epub 2012 Jun 27.

PMID:
22736395
16.

Strict glycemic control and mortality risk among US adults with type 2 diabetes.

Davila EP, Florez H, Trepka MJ, Fleming LE, Niyonsenga T, Lee DJ, Parkash J.

J Diabetes Complications. 2011 Sep-Oct;25(5):289-91. doi: 10.1016/j.jdiacomp.2011.03.004. Epub 2011 Jun 11.

PMID:
21658973
17.

Predicting type 2 diabetes mellitus using haemoglobin A1c: a community-based historic cohort study.

Lerner N, Shani M, Vinker S.

Eur J Gen Pract. 2014 Jun;20(2):100-6. doi: 10.3109/13814788.2013.826642. Epub 2013 Nov 29.

PMID:
24286159
19.

Longitudinal change in HbA1c after insulin initiation in primary care patients with type 2 diabetes: a database analysis in UK and Germany.

Rathmann W, Strassburger K, Tamayo T, Kostev K.

Prim Care Diabetes. 2012 Apr;6(1):47-52. doi: 10.1016/j.pcd.2011.10.001. Epub 2011 Nov 17.

PMID:
22099215
20.

Haemoglobin A1c goal attainment in relation to dose in patients with diabetes mellitus taking metformin: a nested, case-control study.

Penning-van Beest FJ, Wolffenbuttel BH, Herings RM.

Clin Drug Investig. 2008;28(8):487-93.

PMID:
18598094
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk